BioInvent International

Director's Dealing • May 6, 2016

PRESS RELEASE 6 May 2016

BioInvent's Board Director Dharminder Chahal increases his shareholding in the company

Lund, Sweden – 6 May – BioInvent International (BINV) today announced that Mr. Dharminder Chahal has increased his shareholding in BioInvent by the acquisition of 13,980,000 shares. Following the transaction, Mr. Chahal holds 14,206,148 shares, corresponding to 5.02 percent of the outstanding shares and votes in BioInvent. Prior to this transaction, Mr. Chahal held 226,148 shares in the company.

Dharminder Chahal is a Board Director of BioInvent since 2013.

To the editors:

About BioInvent

BioInvent International AB develops immune oncology drugs. With one of the world's largest antibody libraries, and a unique, proprietary discovery method, BioInvent can identify the optimal cellular targets and antibodies for the treatment of various tumor types. BioInvent has also considerable experience in, and a facility for, process development and production of antibodies for clinical studies. This makes it possible to develop proprietary drug projects and also to supply leading international pharmaceutical companies with effective tools for their drug development. BioInvent currently has three proprietary projects in or close to clinical development and partnership agreements with seven global pharmaceutical and biotech companies. More information is available at www.bioinvent.com.

For further information, please contact:

Michael Oredsson President and CEO +46 (0)46 286 85 67 +46 (0)70716 89 30 michael.oredsson@bioinvent.com

BioInvent International AB (publ)

Co. reg. No: 556537-7263 Visiting address: Sölvegatan 41 Mailing address: 223 70 LUND Phone: +46(0)46 286 85 50 info@bioinvent.com www.bioinvent.com

The press release contains statements about the future, consisting of subjective assumptions and forecasts for future scenarios. Predictions for the future only apply as of the date they are made and are, by their very nature, in the same way as research and development work in the biotech segment, associated with risk and uncertainty. With this in mind, the actual outcome may deviate significantly from the scenarios described in this press release.

Information disclosed in this press release is provided herein pursuant to the Swedish Securities Markets Act and/or the Swedish Financial Instruments Trading Act. The information was submitted for publication at 8.40 a.m. CET, on 6 May 2016.